279 related articles for article (PubMed ID: 15054035)
1. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials.
Als-Nielsen B; Gluud LL; Gluud C
BMJ; 2004 May; 328(7447):1046. PubMed ID: 15054035
[TBL] [Abstract][Full Text] [Related]
2. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Gluud LL; Vilstrup H; Morgan MY
Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
[TBL] [Abstract][Full Text] [Related]
3. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Gluud LL; Vilstrup H; Morgan MY
Cochrane Database Syst Rev; 2016 May; 2016(5):CD003044. PubMed ID: 27153247
[TBL] [Abstract][Full Text] [Related]
4. Nonabsorbable disaccharides for hepatic encephalopathy.
Als-Nielsen B; Gluud LL; Gluud C
Cochrane Database Syst Rev; 2004; (2):CD003044. PubMed ID: 15106187
[TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
Zacharias HD; Zacharias AP; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790
[TBL] [Abstract][Full Text] [Related]
6. Current state of knowledge of hepatic encephalopathy (part III): non-absorbable disaccharides.
Morgan MY
Metab Brain Dis; 2016 Dec; 31(6):1361-1364. PubMed ID: 27638474
[TBL] [Abstract][Full Text] [Related]
7. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Goh ET; Stokes CS; Sidhu SS; Vilstrup H; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2018 May; 5(5):CD012410. PubMed ID: 29762873
[TBL] [Abstract][Full Text] [Related]
8. Disaccharides in the treatment of hepatic encephalopathy.
Sharma P; Sharma BC
Metab Brain Dis; 2013 Jun; 28(2):313-20. PubMed ID: 23456517
[TBL] [Abstract][Full Text] [Related]
9. Probiotics for patients with hepatic encephalopathy.
McGee RG; Bakens A; Wiley K; Riordan SM; Webster AC
Cochrane Database Syst Rev; 2011 Nov; (11):CD008716. PubMed ID: 22071855
[TBL] [Abstract][Full Text] [Related]
10. Probiotics for people with hepatic encephalopathy.
Dalal R; McGee RG; Riordan SM; Webster AC
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD008716. PubMed ID: 28230908
[TBL] [Abstract][Full Text] [Related]
11. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2015 Feb; (2):CD001939. PubMed ID: 25715177
[TBL] [Abstract][Full Text] [Related]
12. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?
Gluud LL; Dam G; Borre M; Les I; Cordoba J; Marchesini G; Aagaard NK; Vilstrup H
Metab Brain Dis; 2013 Jun; 28(2):221-5. PubMed ID: 23275147
[TBL] [Abstract][Full Text] [Related]
13. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2017 May; 5(5):CD001939. PubMed ID: 28518283
[TBL] [Abstract][Full Text] [Related]
14. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2015 Sep; (9):CD001939. PubMed ID: 26377410
[TBL] [Abstract][Full Text] [Related]
15. Acetyl-L-carnitine for patients with hepatic encephalopathy.
Martí-Carvajal AJ; Gluud C; Arevalo-Rodriguez I; Martí-Amarista CE
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD011451. PubMed ID: 30610762
[TBL] [Abstract][Full Text] [Related]
16. Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis.
Cammà C; Fiorello F; Tinè F; Marchesini G; Fabbri A; Pagliaro L
Dig Dis Sci; 1993 May; 38(5):916-22. PubMed ID: 8482191
[TBL] [Abstract][Full Text] [Related]
17. First and second generation non absorbable disaccharides in the treatment of hepatic encephalopathy.
Capocaccia L; Riggio O; Merli M
Ital J Gastroenterol; 1990 Dec; 22(6):365-7. PubMed ID: 2131958
[No Abstract] [Full Text] [Related]
18. Pharmacotherapy for hepatic encephalopathy.
Phongsamran PV; Kim JW; Cupo Abbott J; Rosenblatt A
Drugs; 2010 Jun; 70(9):1131-48. PubMed ID: 20518580
[TBL] [Abstract][Full Text] [Related]
19. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomised, cross-over study.
Morgan MY; Alonso M; Stanger LC
J Hepatol; 1989 Mar; 8(2):208-17. PubMed ID: 2654285
[TBL] [Abstract][Full Text] [Related]
20. Comparative modes of action of lactitol and lactulose in the treatment of hepatic encephalopathy.
Patil DH; Westaby D; Mahida YR; Palmer KR; Rees R; Clark ML; Dawson AM; Silk DB
Gut; 1987 Mar; 28(3):255-9. PubMed ID: 3570029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
